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Abstract
Background: Hyperlipasemia is frequent in critically ill people without evidence of
acute pancreatitis (AP), and has been associated with increased morbidity and
mortality.
Objective: To evaluate the prevalence of hyperlipasemia at admission and develop-
ment of hyperlipasemia during hospitalization in critically ill dogs, explore factors
associated with hyperlipasemia, and evaluate association with outcome.
Animals: Critically ill, client owned dogs (n = 1360), presented on emergency and
admitted to the intensive care unit, that had 1,2-o-dilauryl-rac-glycero-3-glutaric
acid-(60-methylresorufin) ester (DGGR) lipase activity measured within 24 hours of
admission.
Methods: Retrospective cross-sectional study of clinical and laboratory records.
Results: The DGGR lipase activity was increased >3× the upper reference limit at
admission in 216/1360 (16%) dogs, of which 70/216 (32%) had a clinical diagnosis of
AP. Other primary conditions associated with hyperlipasemia were renal, endocrine,
and immune-mediated diseases, and upper airway obstruction. Predictors of hyper-
lipasemia at admission were prior glucocorticoid administration, vomiting and abdom-
inal pain, increased age, plasma bilirubin and creatinine concentrations, and
decreased hematocrit. Of dogs with repeat measurements, 78/345 (23%) had signifi-
cantly increased lipase during hospitalization, of which 13/78 (17%) had a clinical
diagnosis of AP. Other primary conditions associated with in-hospital hyperlipasemia
were renal and immune-mediated disorders. Predictors of developing hyperlipasemia
Abbreviations: ALP, alkaline phosphatase activity; ALT, alanine transaminase activity; AP, acute pancreatitis; CI, confidence interval; cPL, canine pancreatic-specific lipase; DGGR, 1,2-o-dilauryl-
rac-glycero-3-glutaric acid-(60-methylresorufin) ester; DKA, diabetic ketoacidosis; gGT, γ-glutamyl transferase activity; GLDH, glutamate dehydrogenase activity; HL group, hyperlipasemic group;
ICU, intensive care unit; IQR, interquartile range; NIL group, nonsignificant increase in lipase group; NL group, nonhyperlipasemic group; SIL group, significant increase in lipase group; URL, upper
reference limit.
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during hospitalization were hemodialysis events, increased plasma bilirubin and creat-
inine concentrations, and decreased hematocrit. Hyperlipasemia both at admission
and during hospitalization was associated with longer hospitalization and higher
mortality.
Conclusions and Clinical Importance: Significant DGGR-hyperlipasemia is frequent in
critically ill dogs and associated with a variety of nonpancreatic conditions and nega-
tive outcome.
K E YWORD S
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1 | INTRODUCTION
Increased serum pancreatic enzyme activities, namely hyperlipasemia
and hyperamylasemia, occur in 14%-80% of people with no prior pan-
creatic disease in intensive care units (ICU), depending on study popu-
lation and enzyme activity cut-offs.1-3 Some of these patients may
develop acute pancreatitis (AP) while undergoing treatment for an
unrelated disorder, mainly because of splanchnic ischemia, sepsis, or
drug administration. However, only up to 35% of patients with pan-
creatic hyperenzymemia have clinical and imaging findings consistent
with AP.2,4,5 In others, clinically irrelevant hyperenzymemia is
suspected and is believed to be associated with a variety of disorders,
including head injury or intracranial events, hepatobiliary disease,
malignancy, diabetic ketoacidosis (DKA), bowel obstruction, perfora-
tion, or both, and renal disease.1,3,4,6-8 Some studies have reported
longer hospital stays4 or higher mortality6 in patients with pancreatic
hyperenzymemia, but others contradict these findings.9 Given that a
diagnosis of AP in both people and dogs relies largely on a combina-
tion of clinical signs, measurement of pancreatic enzymes, and diag-
nostic imaging,10 distinguishing true AP from clinically irrelevant
hyperenzymemia is particularly challenging in critically ill individuals in
the face of comorbidities with clinical signs that may mimic AP.
The most commonly used assays in the diagnostic evaluation of
AP in people are serum amylase and lipase activities,10 but canine
pancreatic-specific lipase concentration (cPL) is currently regarded as
the most accurate blood test in dogs, whereby concentrations
≥400 μg/L are reported to have sensitivities and specificities of 21%-
78% and 80%-100%, respectively, with sensitivity increasing with
severity of disease.11-15 A point-of-care test (SNAP cPL) for patient-
side measurement of cPL has been developed, using a cutoff of
≥200 μg/L, which reportedly has higher sensitivity (82%-93%) but
lower specificity (59%-74%).13,16 These studies also indicated poor
performance of the 1,2-diglyceride lipase assay for the diagnosis of
AP. However, evaluation of the more recently validated 1,2-o-
dilauryl-rac-glycero-3-glutaric acid-(60-methylresorufin) ester (DGGR)
lipase assay17 found high agreement with cPL.18
Besides AP, conditions associated with increased lipase activity or
cPL in dogs include septic peritonitis, gastrointestinal foreign body,
gastric dilatation-volvulus, gastroenteritis, pancreatic or hepatic
neoplasia, cardiac disease, DKA, obesity, Ehrlichia canis or Babesia rossi
infection, hyperadrenocorticism, and glucocorticoid administra-
tion.16,19-29 Some of these disorders may cause secondary AP because
of diffuse abdominal inflammation, pancreatic hypoperfusion or ische-
mia and reperfusion.16 However, the clinical relevance of hyper-
lipasemia in many cases remains unclear, as does the influence of
renal disease on lipase activity.
Although an association between hyperlipasemia and certain spe-
cific conditions has been investigated in dogs, the prevalence of
hyperlipasemia in critically ill dogs in the ICU is unknown, and factors
associated with hyperlipasemia in these dogs remain to be elucidated.
Given the incorporation of lipase assays in routine biochemical pro-
files at some institutions, including ours, such knowledge is important
to help assess the relevance of hyperlipasemia in critically ill dogs.
Therefore, our aims were to: (a) evaluate the prevalence of
DGGR-hyperlipasemia in critically ill dogs at admission and during
hospitalization, (b) determine factors associated with hyperlipasemia,
and (c) evaluate the association between hyperlipasemia and duration
of hospitalization and mortality. We hypothesized that DGGR-
hyperlipasemia is frequent in critically ill dogs with disorders unrelated
to AP and is associated with increased duration of hospitalization and
mortality.
2 | METHODS
The electronic medical records and laboratory database were retro-
spectively searched for dogs presented to the Small Animal Clinic,
Vetsuisse Faculty, University of Berne, Switzerland between April
2015 and April 2017. All dogs presented during this period were
included in the study if they were considered critically ill and if a
plasma biochemical profile that included DGGR-lipase was performed
within 24 hours of admission. Dogs were considered critically ill based
on emergency presentation and immediate admission to the ICU,
regardless of clinical signs or affected organ system. For dogs that
were admitted on >1 occasion during the study period, only the most
recent admission was included.
Data collected included signalment, clinical signs at admission
considered consistent with AP (anorexia, vomiting, abdominal pain,
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diarrhea),30 clinical diagnosis, treatment with glucocorticoids within
7 days before admission, duration of hospitalization, and outcome
defined as discharge or death or euthanasia. All clinical diagnoses of AP
were made by a board-certified internal medicine or emergency and crit-
ical care specialist, or an intern or resident under their close supervision.
Cases were considered to be primary AP if a clinical diagnosis of AP was
recorded as the primary clinical diagnosis, and secondary AP if it was
suspected to have developed during hospitalization in dogs with another
primary clinical diagnosis. Results of ultrasonographic examination, per-
formed by a board-certified radiologist or a diagnostic imaging resident
under direct supervision of a board-certified radiologist, were included if
performed within 48 hours of admission.
Clinicopathologic data collected included initial and all further
measurements of DGGR-lipase activity using a previously validated
assay,17 as well as simultaneous automated measurements of hemato-
crit (ADVIA 2120i, Siemens Healthcare, Zürich, Switzerland) and
selected biochemistry analytes (Cobas c501, Roche Diagnostics, Basel,
Switzerland), including alanine transaminase activity (ALT), albumin,
alkaline phosphatase activity (ALP), bilirubin, creatinine, C-reactive
protein, γ-glutamyl transferase activity (gGT), and glutamate dehydro-
genase activity (GLDH). Samples were submitted for simultaneous
Spec cPL measurements (IDEXX Diavet, Bäch, Switzerland) at the clini-
cians' discretion; published cut-offs for normal results (0-200 μg/L),
equivocal (201-399 μg/L), and consistent with pancreatitis (≥400 μg/L)
were used.15 In addition, abdominal surgery, anesthesia and hemodial-
ysis performed between initial and subsequent DGGR-lipase measure-
ments were documented.
Dogs were categorized into the hyperlipasemic (HL) group if
DGGR-lipase activity measured within 24 hours of admission
exceeded 3× the URL (>324 U/L) and into the nonhyperlipasemic
(NL) group if they had DGGR-lipase activity within 3× of the upper
reference limit (URL, <325 U/L). This cut-off was chosen based on the
definition of clinically relevant hyperlipasemia used in previous studies
in people and dogs.5,7,8,10,30,31 For those dogs with subsequent
DGGR-lipase measurements during hospitalization, the first result
measured within 24 hours of admission served as baseline, and only
the highest repeated measured activity was additionally included in
the data analysis. A clinically relevant in-hospital increase in DGGR-
lipase was arbitrarily defined as a value >3× the URL and also >2× the
value at admission, and dogs were thus further grouped as nonsignifi-
cant increase in lipase (NIL) group or significant increase in lipase (SIL)
group (Figure 1).
2.1 | Statistical analysis
Statistical analysis was performed using MedCalc Statistical Software
version 17.8.1. Data were assessed for normality using D'Agostino-
F IGURE 1 Flow diagram documenting case enrollment and classification. Dogs initially assessed for eligibility included all dogs presented to
our institution between April 2015 and April 2017 which had a DGGR lipase measurement performed in our laboratory as part of their current
visit. URL, upper reference limit
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Pearson tests and by evaluation of normal plots. Because most data
were non-normally distributed, nonparametric analyses were per-
formed. Comparisons between groups were analyzed using chi-
squared tests and Mann-Whitney tests for categorical and ordinal
data, respectively. The association between demographic, clinical and
clinicopathologic factors and lipase groups was evaluated using uni-
variate logistic regression. Predictors significantly associated with
lipase groups were further analyzed using multivariate logistic regres-
sion in a stepwise selection fashion. Spearman's rank correlation was
used to assess the association between DGGR-lipase activity and
plasma creatinine concentrations. Cohen's kappa was used to assess
agreement between a clinical and sonographic diagnosis of
AP. Statistical significance was set at P < .05 throughout.
3 | RESULTS
3.1 | Study population demographics
During the study period, 4074 DGGR-lipase assays were performed
on 2856 dogs. Of these, 1360 dogs met the inclusion criteria. Dogs
represented 172 breeds, the most common being mixed breed
(n = 191), Labrador Retriever (n = 79), French Bulldog (n = 55), York-
shire Terrier (n = 54), Chihuahua (n = 48), Golden Retriever (n = 47),
Bernese Mountain dog (n = 44), Jack Russell terrier (n = 43), and Ger-
man Shepherd (n = 35). Data regarding age, sex, and body weight at
admission were missing from the medical records in 11, 3, and
77 dogs, respectively. Data from the remaining dogs are presented in
Table 1.
3.2 | Differences between lipase groups
The DGGR-lipase activity measured at admission ranged from 7 to
19 700 U/L. A total of 1144 (84%) dogs were assigned to the NL
group, of which 843 (62%) and 301 (22%) had DGGR-lipase activities
below the URL and between 1× and 3× the URL, respectively. A fur-
ther 216 (16%) dogs, with DGGR-lipase activities >3× the URL, were
assigned to the HL group (Table 1, Figure 1).
The median age of dogs in the NL group was slightly lower than
in the HL group, but no difference between the groups was found for
sex or body weight (Table 1). Dogs in the HL group were significantly
more likely to have clinical signs considered consistent with AP than
were dogs in the NL group (Table 1), and more commonly had several
of these signs (data not shown). Data regarding previous drug admin-
istration were available for 1357 dogs. A total of 93 dogs had received
glucocorticoids, of which 69/1142 (6%) and 24/215 (11%) were in the
NL and HL groups, respectively. Glucocorticoids administered before
presentation included both prednisolone and dexamethasone, and
were prescribed to dogs in all disease categories, but predominantly in
dogs with immune-mediated and lung disease, as well as
gastroenteritis.
TABLE 1 Clinical data from 1360 critically ill dogs with DGGR-lipase activities at admission within 3× (NL group) and above 3× (HL group)
the upper reference limit
Variable All dogs NL group HL group P value
Number of dogs 1360 1144 (84%) 216 (16%)
DGGR-lipase, U/L
range 7-19 700 7-295 369-19 700
median (IQR) 71 (38-174) 59 (35-113) 1140 (566-2081)
Age, median (IQR), years 7.5 (3.6-10.3) 7.2 (3.3-10.1) 8.7 (5.5-10.9) <.001
Body weight, median (IQR), kg 18.0 (7.8-30.0) 18.5 (7.9-30.0) 14.9 (7.4-30.0) .342
Sex
Female 647 (433 spayed) 556 (367 spayed) 91 (66 spayed) .08
Male 710 (341 castrated) 585 (269 castrated) 125 (72 castrated)
Clinical signs at presentation
Anorexia 393 (29%) 318 (28%) 75 (35%) .04
Vomiting 575 (42%) 452 (40%) 123 (57%) <.001
Diarrhea 322 (24%) 254 (22%) 68 (32%) .003
Abdominal pain 233 (17%) 182 (16%) 51 (24%) .006
Diagnosis of acute pancreatitis
Clinical 95 (7%) 25 (2%) 70 (32%) <.001
Sonographic 102/720 (14%) 55/572 (10%) 47/148 (32%) <.001
Duration of hospitalization, median (IQR), days 4 (3-7) 4 (3-6) 5 (3-8) .006
Mortality 325 (24%) 255 (22%) 70 (32%) .001
Abbreviation: IQR, interquartile range.
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Plasma albumin concentration and hematocrit were significantly
lower in dogs of the HL group, whereas ALT, ALP, bilirubin, creatinine,
gGT, and GLDH were significantly higher (P < .001; Supplemental
Table 1).
3.3 | Predictors of lipase groups
Demographic data (age, sex, body weight), clinical signs at admis-
sion, prior glucocorticoid administration, and clinicopathologic data
found to be significant predictors of HL group in univariate analyses
were age, prior administration of glucocorticoids, anorexia, vomiting,
diarrhea, abdominal pain, creatinine, bilirubin, ALT, ALP, gGT, GLDH,
and hematocrit (data not shown). In multivariate analysis, only age,
vomiting, abdominal pain, prior administration of glucocorticoids,
creatinine, bilirubin, and hematocrit were found to be independent
predictors of lipase group (Table 2). The correlation (Spearman's
rank) between DGGR-lipase activity and plasma creatinine concen-
trations in all dogs was poor at 0.22 (95% confidence intervals [CI],
0.17-0.27).
3.4 | Clinical and sonographic diagnoses
A total of 95 (7%) dogs were considered to have clinical AP either as a
primary or secondary disorder. Of these, 70 were classified in the HL
group (Table 1). Thus, 146/216 (68%) dogs in the HL group were not
diagnosed with AP and 25/1144 (2%) dogs in the NL group were
diagnosed with AP. Nonetheless, a clinical diagnosis of AP was signifi-
cantly associated with lipase group (Table 1), and the median DGGR-
lipase activity in dogs with and without a diagnosis of AP was
1136 U/L (interquartile range [IQR], 258-2280 U/L) and 65 U/L (IQR,
37-143 U/L), respectively.
For the 720 dogs that underwent abdominal ultrasound examina-
tion within 48 hours of admission, 102 (14%) were given a sono-
graphic diagnosis of AP. This outcome was significantly associated
with lipase group (Table 1), and the median lipase activity in dogs with
and without a sonographic diagnosis of AP was 245 U/L (IQR,
74-1542 U/L) and 83 U/L (IQR, 41-186 U/L), respectively. The kappa
agreement between a clinical and a sonographic diagnosis of AP was
0.47 (95% CI, 0.37-0.56).
A clinical diagnosis of primary AP was given to 61 (4.5%)
dogs. These included 46/216 (21%) and 15/1144 (1.3%) dogs in
the HL and NL groups, respectively. The most common other
primary diseases in the HL group were renal, endocrine (predomi-
nantly diabetes mellitus and hypoadrenocorticism) and immune-
mediated disorders, as well as upper airway obstruction (Figure 2).
A list of diseases included as “others” is provided in Supplemental
Table 2.
3.5 | Duration of hospitalization and outcome
The duration of hospitalization ranged from 1 to 35 days, with shorter
median hospitalization in the NL group compared to the HL group
(Table 1). Overall, mortality was 24%, and differed slightly but signifi-
cantly between groups (Table 1, Figure 3A) with mortality likelihood
ratios of 0.91 (95% CI, 0.86-0.97) and 1.53 (95% CI, 1.18-1.97) in the
NL and HL groups, respectively.
3.6 | Dogs with repeated measurements of DGGR-
lipase activity
Repeat DGGR-lipase measurements were performed 518 times in
345 dogs during hospitalization with activities ranging from 8 to
20 700 U/L (Table 3). In 126/345 (37%) dogs, the maximum repeat
value was greater than 2× the value at admission. In 78/345 (23%)
dogs, values also were >3× the URL, and these dogs were assigned to
the significant increase group (SIL). The remaining 267 dogs were
assigned to the nonsignificant increase group (NIL). Hematocrit was
significantly lower in dogs of the SIL group, whereas plasma bilirubin
and creatinine concentrations were significantly higher (P < .001; Sup-
plemental Table 3).
TABLE 2 Multivariate logistic
regression of demographic, clinical, and
clinicopathologic data independently
associated with HL group
Independent variable (predictor) Coefficient SE P value OR 95% CI
Age, years 0.090 0.021 <.001 1.09 1.05-1.14
History of vomiting 0.602 0.170 <.001 1.83 1.31-2.55
Abdominal pain on presentation 0.396 0.198 .05 1.49 1.01-2.19
Prior administration of glucocorticoids 0.808 0.271 .003 2.24 1.32-3.82
Creatinine (mg/dL) 0.166 0.027 <.001 1.18 1.12-1.24
Bilirubin (mg/dL) 0.085 0.027 .002 1.09 1.03-1.15
Hematocrit (%) −0.021 0.007 .004 0.98 0.97-0.99
constant −2.329 0.358 <.001
Notes: Predictor variables analyzed in univariate analysis but found nonsignificant and not included in the
model were albumin, anorexia at presentation, alkaline phosphatase, alanine aminotransferase, diarrhea
at presentation, gamma glutamate transferase, and glutamate dehydrogenase.
Abbreviations: CI, confidence interval; OR, odds ratio (adjusted).
PRÜMMER ET AL. 2323
3.7 | Predictors of in-hospital increase in lipase
Demographic data, clinical signs at admission, clinicopathologic data,
and anesthesia, surgery or hemodialysis events found to be predic-
tors of SIL group in univariate analyses were creatinine, bilirubin,
and hematocrit measured simultaneously with the repeat DGGR-
lipase measurement, and hemodialysis between initial and repeat
measurements (data not shown). These 4 predictors were
maintained as independent predictors of SIL group in multivariate
analysis (Table 4).
3.8 | Clinical diagnoses in repeat lipase groups
For dogs with repeated measurement of DGGR-lipase, 53/345 (15%)
dogs were considered to have clinical AP, of which only 13/78 (17%)
dogs were in the SIL group (Table 3). A primary diagnosis of AP was
given to 31/345 dogs with repeat DGGR-lipase measurements. These
were 3/78 (4%) and 28/267 (10%) dogs in the SIL and NIL groups,
respectively. The most common other primary diseases in the SIL
group were renal and immune-mediated disorders (Figure 4). A list of
diseases included as “others” is provided in Supplemental Table 4. No
F IGURE 2 Primary disorders associated with admission DGGR-lipase activities below (NL; gray) and above (HL; blue) 3× the upper reference
limit in critically-ill dogs. Numbers of dogs in each group are shown within bars
F IGURE 3 A, Outcome of 1360 critically ill dogs with DGGR-lipase activities at admission within 3× (NL group) and above 3× (HL group) the
upper reference limit (dark blue, death; gray, discharge). Mortality differed significantly between groups (P = .001). B, Outcome of 345 critically ill
dogs with nonsignificant (NIL) and significant (SIL) increases in DGGR-lipase activities during hospitalization (dark blue, death; gray, discharge).
Mortality differed significantly between groups (P = .01)
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TABLE 3 Clinical data and outcome associated with nonsignificant (NIL) and significant (SIL) increases in DGGR-lipase activities during
hospitalization in 345 critically ill dogs
Variable All dogs NIL group SIL group P value
Number of dogs 345 267 78
Admission DGGR-lipase, U/L
Range 7-15 616 7-15 616 18-4746
Median (IQR) 95 (43-263) 76 (39-262) 139 (71-281)
Repeat DGGR-lipase, U/L
Range 8-20 700 8-13 700 433-20 700
Median (IQR) 143 (56-895) 94 (45-207) 1656 (962-3732)
Clinical diagnosis of acute pancreatitis 53 (15%) 40 (15%) 13 (17%) <.001
Events between lipase measurements
Anesthesia 37 (11%) 31 (12%) 6 (8%) .326
Abdominal surgery 56 (16%) 41 (15%) 15 (19%) .415
Hemodialysis 21 (6%) 1 (0%) 20 (26%) <.001
Duration of hospitalization, median (IQR), days 7 (5-11) 7 (5-9) 10 (7-14) <.001
Mortality 63 (18%) 41 (15%) 22 (28%) .01
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; CRP, C-reactive protein; gGT, gamma glutamyl transferase; GLDH, glutamate
dehydrogenase; IQR, interquartile range.
TABLE 4 Multivariate logistic
regression of demographic, clinical, and
clinicopathologic data independently
associated with SIL group
Independent variable (predictor) Coefficient SE P value OR 95% CI
Creatinine (mg/dL) 0.307 0.085 <.001 1.36 1.15-1.61
Bilirubin (mg/dL) 0.125 0.052 .02 1.13 1.02-1.26
Hematocrit (%) −0.054 0.018 .003 0.95 0.92-0.98
Hemodialysis 2.484 1.122 .03 11.99 1.33-108.05
Constant −2.299 0.643 .643
Abbreviations: CI, confidence interval; OR, odds ratio (adjusted).
F IGURE 4 Primary disorders
associated with nonsignificant
(NIL; gray) and significant (SIL;
blue) increases in DGGR-lipase
activity during hospitalization in
345 critically ill dogs. Numbers of
dogs in each group are shown
within bars
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association was found between groups and anesthesia or abdominal
surgery between initial and repeat DGGR-lipase measurements, but
20/21 dogs undergoing hemodialysis were in the SIL group (Table 3).
3.9 | Duration of hospitalization and outcome in
repeat lipase groups
Significantly shorter hospitalization was recorded in the NIL group
compared to the SIL group (Table 3). Overall mortality of dogs with
repeat lipase measurements was 18% and differed significantly
between groups (Table 3, Figure 3B), with mortality likelihood ratios
of 0.81 (95% CI, 0.67-0.98) for the NIL group and 1.76 (95% CI,
1.17-2.65) for the SIL group.
3.10 | Simultaneous measurements of cPL
In 71/1360 dogs, cPL was measured from the same sample used to
measure DGGR-lipase. The cPL was 0-200 μg/L in 38 samples,
201-399 μg/L in 8 samples and ≥400 μg/L in 25 samples. Of dogs
with cPL ≥400 μg/L, 20/25 (80%) were in the HL group, whereas all
dogs with cPL <400 μg/L were in the NL group (Figure 5).
4 | DISCUSSION
To our knowledge, this study is the first to evaluate the prevalence of
and factors associated with DGGR-hyperlipasemia in a large cohort of
critically ill dogs. We found an increase in lipase activity >3 URL in
16% of the examined population at admission, of which only approxi-
mately one-third was suspected to have AP based on clinical and
ultrasonographic findings. This finding suggests that significantly
increased DGGR-lipase activity is common in critically ill dogs at
admission without overt clinical AP. This finding is comparable to
studies in people in which 14%-80% of patients admitted to ICU had
hyperlipasemia, with only up to 35% meeting criteria to diag-
nose AP.1-5
The most common nonpancreatic disorder associated with an
increased lipase activity in our study was renal disease, despite poor
correlation between DGGR-lipase activity and plasma creatinine con-
centration. The effect of decreased GFR, because of naturally occur-
ring or experimentally induced acute kidney injury and chronic kidney
disease on lipase activity has been variably reported in the literature,
with older reports suggesting that lipase activity is increased in renal
disease,32 but newer studies not documenting significant effects of
experimentally induced acute kidney injury33 and chronic renal fail-
ure34 on lipase activity and cPL. The kidneys are considered to be a
major site for lipase metabolism, likely through a combination of glo-
merular filtration, tubular reabsorption, and enzyme inactivation,35
which would explain why hyperlipasemia cannot be accounted for by
decreased GFR alone. In our study, despite choosing a conservative
cut-off for DGGR-lipase activity, renal disease remained a common
diagnosis in dogs with hyperlipasemia, and was furthermore associ-
ated with a significant increase in lipase activity during hospitalization.
Noteworthy was that patients undergoing hemodialysis frequently
experienced a marked increase in DGGR-lipase activity during hospi-
talization. Increased cPL recently has been reported in a large propor-
tion of dogs undergoing hemodialysis for acute kidney injury, but cPL
was measured at any time within 7 days before or after admission and
no further testing (such as imaging) was described to confirm the diag-
nosis of pancreatitis.36 People undergoing dialysis, particularly perito-
neal dialysis, have been reported to have higher risk for developing
pancreatitis.37 Furthermore, heparin used as an anticoagulant during
hemodialysis also has been shown to stimulate lipoprotein lipase and
thus cause significant increases in lipase activity in absence of pancre-
atitis.38 In our study population, citrate more commonly was used as
an anticoagulant for dogs undergoing dialysis. Therefore, we hypothe-
size that the significant in-hospital increase in DGGR-lipase activity
observed in 20/21 dogs in our study is more likely a reflection of sub-
clinical pancreatic damage than of lipoprotein lipase induction. Possi-
ble reasons for this conclusion extrapolated from human medicine
include inflammation secondary to the underlying disorder causing
renal injury, multiorgan failure, and ischemia or hypoperfusion
because of changes in plasma volume.4,9,39
Other primary nonpancreatic disorders frequently associated with
significantly increased DGGR-lipase activities in our study were endo-
crinopathies, immune-mediated disorders, and upper airway obstruc-
tion. Diabetes mellitus and AP are common comorbidities; a previous
study found diabetes mellitus in 36% of dogs diagnosed with AP,40
and another identified cPL concentrations >400 μg/L in 73% of dogs
with DKA.24 In people, type 2 diabetes mellitus is associated with
increased risk of AP,41 but nonspecific hyperlipasemia without evi-
dence of AP on cross-sectional imaging also was common in patients
with DKA.42 These studies suggest that although AP is associated with
diabetes mellitus and DKA in dogs and people, nonspecific increases
F IGURE 5 Results of simultaneous measurements of DGGR-
lipase and cPL measured in 71 critically-ill dogs. The blue dashed line
indicates 3× the upper reference limit for DGGR-lipase activity used
to denote significant increased activity
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in pancreatic enzymes apparently also occur, and both may partly
explain the association between increased DGGR-lipase activity and
endocrinopathies observed in our study. Diabetes mellitus and other
endocrinopathies, such as hyperadrenocorticism and hypothyroidism,
are associated with AP, possibly because of a combination of hyperlip-
idemia, decreased insulin sensitivity, and increased proinflammatory
cytokines.24,43
Increased cPL with questionable clinical relevance previously has
been described in dogs with various immune-mediated disorders
treated with prednisolone.29 Although drug administration could be
suspected to be a major contributing factor, other studies have shown
that steroid administration did not cause an increase in cPL concentra-
tions above reference intervals in healthy dogs.44,45 We did observe a
significantly higher number of patients with prior corticosteroid
administration in the HL group, but this finding may reflect the under-
lying primary disease, including immune-mediated disorders and hypo-
adrenocorticism, rather than direct drug effects.
Hyperlipasemia has to our knowledge not yet been described in
association with upper airway obstruction in dogs, but abnormalities
of the upper gastrointestinal tract have been identified in the majority
of brachycephalic dogs with upper respiratory syndrome, including
patients without gastrointestinal clinical signs.46 Despite that study
not specifically examining the pancreas, it raises the question of sub-
clinical AP possibly being an explanation for the relatively high preva-
lence of upper airway obstruction in the HL group of our study. The
latter however could also simply reflect the high prevalence of French
Bulldogs in our patient population, rather than a true association with
pancreatitis.
In addition to the substantial number of dogs presenting with
DGGR-hyperlipasemia, 23% of our dogs with repeated measurements
had a significant in-hospital increase in DGGR-lipase activity. This
phenomenon also has been reported in people admitted to ICU, and is
hypothesized to be linked to underlying inflammation, hypoperfusion,
and multiorgan failure.4,9,39 One study found that hyperlipasemia was
associated with anemia, increased serum creatinine concentration,
and hyperbilirubinemia, and thus was interpreted as a pancreatic man-
ifestation of multisystem organ failure.4 This possibility also could
explain the association of higher plasma bilirubin and creatinine con-
centrations and lower hematocrit in our dogs with DGGR-
hyperlipasemia at admission or during hospitalization. It must be
noted however that dogs with clinically unstable conditions such as
hypotension, multiple organ dysfunction, and sepsis are more likely to
have repeated plasma biochemistry performed, which possibly has
artificially inflated the prevalence of SIL in our retrospective study.
Hyperlipasemia and in-hospital increases in DGGR-lipase activity
were associated with both increased duration of hospitalization and
mortality in our study. People with hyperlipasemia are reported to
have increased duration of hospitalization, but the effect on mortality
is variable.4,6,9 However, comparison of mortality rates in our popula-
tion is confounded by euthanasia in some dogs because of perceived
poor prognosis or financial constraints, for which we could not
account appropriately because of the retrospective nature of the
study. As such, severity of illness scoring or intention-to-treat analysis
in dogs instead of mortality may be more objective tools for the
assessment of outcome in future studies. Moreover, duration of hos-
pitalization and mortality may differ depending on the type of clinical
setting, and thus findings from our study cannot be assumed to reflect
expected findings in disparate settings.
Our work had several other limitations, the main limitation being
the retrospective study design, which did not allow for the ultrasound
evaluation or the clinical assessment for pancreatitis to be standard-
ized. In absence of histopathology, the diagnosis of pancreatitis in
dogs relies on the combination of nonspecific clinical signs, pancreatic
enzyme assays and ultrasonographic findings. The latter has not
proven to be a reliable diagnostic tool for pancreatitis, with weak to
fair agreement between ultrasonographic diagnosis and presence of
hyperlipasemia in previous studies,18,47 with our findings also
supporting this conclusion. Therefore, the true prevalence of AP in
our population unfortunately could not be reliably established. Lipase
activity often is criticized as being too nonspecific to reliably predict
AP, compared to cPL, which currently is considered the biomarker of
choice for AP with reported specificities of 66%-100%, depending on
cut-off and study design.11-14 However, previous studies18 found
excellent agreement between cPL and DGGR-lipase, which also
seemed to be true in our patient population. The high proportion of
hyperlipasemic animals without a diagnosis of AP in our study there-
fore would suggest that cPL is less specific than previously thought
when applied to a population of critically ill dogs with a clinical picture
comparable to that of AP. Because lipase and cPL results strongly
influenced the clinician's decision to rule in or rule out pancreatitis,
this likely represents a bias in our study, which may have over-
estimated the prevalence of AP, further decreasing the specificity of
these tests. Another major limitation of our study was the lack of a
scoring system such as Acute Patient Physiologic and Laboratory Eval-
uation (APPLE) scores at admission to evaluate the severity of illness.
This score was not determined for the animals enrolled in our study
because of inconsistent availability of data required to formulate such
a score. However, dogs hospitalized in our ICU are the most severely
ill patients in our hospital.
On the other hand, the large and broad study population repre-
sents a major strength of our study. Because DGGR-lipase activity
measurement is incorporated in our plasma biochemical profile for
dogs, the assay is performed on almost every dog admitted to the
ICU, regardless of the clinician's index of suspicion for AP. In contrast,
at our institution, because we do not routinely use the cage-side
SNAP cPL test, cPL is a send-off test only performed on specific
request, presumably based on a clinician's desire to rule in or out a
diagnosis of AP.
In conclusion, critically ill dogs have a relatively high occurrence
of DGGR-hyperlipasemia both at admission and developing during
hospitalization despite a relatively low prevalence of either clinical or
sonographic AP. Factors associated with DGGR-hyperlipasemia
include primary renal disease and hemodialysis, endocrinopathies,
immune-mediated disorders, upper airway obstruction, as well as pre-
vious treatment with corticosteroids. Hyperlipasemia >3× the URL is
associated with longer hospitalization and mortality in critically ill
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dogs, and may be more a marker of multiple organ dysfunction or
ischemia than of clinically relevant AP. As such, clinicians should be
wary of making a diagnosis of AP based solely on DGGR-lipase or cPL
in critically ill dogs.
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